Thymolflex EPA approval

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technologies, is pleased to announce that the Company's partner, Véto-pharma, has received regulatory approval from the US Environmental Protection Agency ("EPA") for Thymolflex® for use in integrated Varroa management. Thymoflex® is a thymol-based treatment used in bee health to control Varroa destructor, an external parasitic mite that attacks and feeds on honey bees. This approval follows an announced agreement, signed by the Company in April 2025, to supply Véto-pharma with thymol for use in bee care products.

Supporting integrated Varroa management strategies

Varroa destructor remains one of the most significant threats to honey bee health worldwide. As resistance concerns increase and environmental conditions become more unpredictable, beekeepers need multiple authorised tools that can be adapted to different colony conditions and management systems.

Thymoflex® is based on thymol, a well-known active substance of natural origin, widely used by beekeepers as part of integrated pest management (IPM) programs.

Thymoflex® is a ready-to-use thymol gel designed for straightforward handling and application in the apiary. The product allows for a controlled release of thymol within the hive, contributing to effective mite control when used according to label directions. Its formulation aims to combine ease of use, consistency, and colony safety, making it suitable for professional beekeeping operations.

By expanding access to thymol-based solutions, Thymoflex® offers beekeepers an additional option to:

• A treatment based on a naturally derived active substance
• Flexible use within the beekeeping season, according to label instructions
• Reduce reliance on a single mode of action
• Proven efficacy against varroa, including in the presence of brood
• Compatibility with treatment rotation programs, helping to manage resistance risks
• Enhance grooming behaviour and overall hygienic responses in honey bee colonies.

The gel formulation enables a homogeneous diffusion of thymol within the hive, contributing to colony safety when used according to label directions.

Availability

Thymoflex® has received EPA federal approval and will be made available to beekeepers in the United States in accordance with individual state registrations.

More information about Thymoflex® will be available soon on the Véto-pharma website: https://www.veto-pharma.com

A long-standing commitment to honey bee health

Honeybee health is affected by multiple factors, including climate change, habitat loss, nutritional stress, pesticide exposure, and pathogens, among which varroa plays a central role. Addressing these challenges requires robust, flexible, and science-based solutions.

For more than 25 years, Véto-pharma has focused exclusively on honey bee health, developing and manufacturing products designed to support beekeepers worldwide in protecting their colonies and securing the future of pollination.

Sean Smith, CEO of Eden Research, commented:

"We are delighted to be able to play such a key role in the delivery of vital care products to keep bee populations thriving. Our partnership with Véto-pharma is representative of our commitment to diversifying our business model and revenue streams by applying our sustainable chemical technology to other sectors beyond arable agriculture."

About Véto-pharma

Founded in 1982, Véto-pharma is a veterinary pharmaceutical laboratory dedicated to honey bee health. The company is recognised globally for its expertise, innovation, and high-quality products developed and manufactured in France.

For more information about Véto-pharma, visit: https://www.veto-pharma.com.